Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.
You may also be interested in...
Pre-Submission Communication Issues May Hurt Regeneron’s Arcalyst In Gout
FDA warned in pre-submission meetings that the company’s safety database may not be adequate and those questions remain as the application goes to the Arthritis Advisory Committee.
With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.